Bevacizumab Versus Triamcinolone Acetonide for the Treatment of Keloids.

Kasr El Aini Hospital

Status and phase: Active, not recruiting; Phase 4

Conditions: Keloids

Treatments: Drug: Triamcinolone Acetonide; Drug: Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT07014280

BevaVSsteroid:keloids

Details and patient eligibility

About

The study compares the efficacy and safety of intralesional bevacizumab versus corticosteroids for the treatment of keloids. Assessment will be done clinically by the use of Modified Vancouver Scar Scale. Erythema index will be measured by spectrophotometry. The levels of Vascular Endothelial Growth Factor, collagen type 1 and collagen type 3 in the lesions before and after each treatment modality.

Enrollment: 28 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with keloids (post-traumatic, any site, any duration)
• Age >18 years
• Patients who didn't receive any treatment for the lesions in the past 6 weeks

Exclusion criteria

• Patients who are pregnant, willing to get pregnant or lactating
• History of any liver or renal disease
• History of any cardiovascular disease
• History of hypertension
• History of thrombo-embolic events
• Known cases of bleeding disorders
• History of peptic ulcer
• Patients who underwent any surgeries in the last month

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

28 participants in 2 patient groups

Intralesional bevacizumab injection

Active Comparator group

Description:

Intralesional bevacizumab injection for the treatment of keloid

Treatment:

Drug: Bevacizumab

Intralesional corticosteroid injection

Active Comparator group

Description:

Intralesional triamcinolone acetonide injection for the treatment of keloids

Treatment:

Drug: Triamcinolone Acetonide